Hormonal
Among patients taking oral semaglutide, older adults (65+) achieve significantly better weight loss outcomes than younger adults (<65).
If you are under 65 and taking the oral version of semaglutide, you might not lose as much weight as older patients on the same medication. If weight loss is your primary goal, the injection form is likely a better choice for you, as it provided superior results across all age groups in this study.
Older oral users experienced better weight loss compared to younger users.
Why this rating
The subgroup of older oral users was very small (n=16), limiting statistical power and robustness.
Source
Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database
Jimmy Kwon et al. · Expert Review of Endocrinology & Metabolism · 2025
DOI 10.1080/17446651.2025.2462100
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →